Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer

Dalton, James T., Taylor, Ryan P., Mohler, Michael L., Steiner, Mitchell S. · 2013 · Current Opinion in Supportive & Palliative Care

Abstract

PURPOSE OF REVIEW: This review highlights selective androgen receptor modulators (SARMs) as emerging agents in late-stage clinical development for the prevention and treatment of muscle wasting associated with cancer. RECENT FINDINGS: Muscle wasting, including a loss of skeletal muscle, is a cancer-related symptom that begins early in the progression of cancer and affects a patient's quality of life, ability to tolerate chemotherapy, and survival. SARMs increase muscle mass and improve physical function in healthy and diseased individuals, and potentially may provide a new therapy for muscle wasting and cancer cachexia. SARMs modulate the same anabolic pathways targeted with classical steroidal androgens, but within the dose range in which expected effects on muscle mass and function are seen androgenic side-effects on prostate, skin, and hair have not been observed. Unlike testosterone, SARMs are orally active, nonaromatizable, nonvirilizing, and tissue-selective anabolic agents. SUMMARY: Recent clinical efficacy data for LGD-4033, MK-0773, MK-3984, and enobosarm (GTx-024, ostarine, and S-22) are reviewed. Enobosarm, a nonsteroidal SARM, is the most well characterized clinically, and has consistently demonstrated increases in lean body mass and better physical function across several populations along with a lower hazard ratio for survival in cancer patients. Completed in May 2013, results for the Phase III clinical trials entitled Prevention and treatment Of muscle Wasting in patiEnts with Cancer1 (POWER1) and POWER2 evaluating enobosarm for the prevention and treatment of muscle wasting in patients with nonsmall cell lung cancer will be available soon, and will potentially establish a SARM, enobosarm, as the first drug for the prevention and treatment of muscle wasting in cancer patients.

Overview

Integrity signals

Registry

Crossref · 10.1097/spc.0000000000000015

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 5 references

Research works printed but not linked: 1

  1. Marcantonio, 2010, A 12-week pharmacokinetic and pharmacodynamic study of two selective androgen receptor Modulators (SARMs) in postmenopausal subjects (Abstract P2-2)., Endocr Rev, 31, S871

Cited by

See all 91

Metadata

Authors
Dalton, J. T., Taylor, R. P., Mohler, M. L., & Steiner, M. S.
Affiliations
GTx (United States) (US)
Corresponding author
Dalton, James T.
Venue
Current Opinion in Supportive & Palliative Care
Published
2013-12
Volume
7
Issue
4
Pages
345-351
ISSN
1751-4258 (ISSN-L)
OpenAlex
W2006607907
Cited by
91
References
5
Citations by year
2026: 8 · 2025: 7 · 2024: 2 · 2023: 6 · 2022: 4 · 2021: 7 · 2020: 8 · 2019: 4 · 2018: 10 · 2017: 10 · 2016: 7 · 2015: 9 · 2014: 9
FWCI
5.79
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Supportive and Palliative Care (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
selective androgen receptor modulators, cancer cachexia, enobosarm, ostarine, skeletal muscle mass, physical function, non-small cell lung cancer, androgenic side effects
MeSH terms
Androgen Antagonists, Cachexia, Humans, Muscular Atrophy, Neoplasms, Receptors, Androgen, Muscle, Skeletal, Anabolic Agents, Androgen Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. https://app.cochat.ai/papers/10.1097/spc.0000000000000015
The paper
Dalton, J. T., Taylor, R. P., Mohler, M. L., & Steiner, M. S. (2013). Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Current Opinion in Supportive & Palliative Care. https://doi.org/10.1097/spc.0000000000000015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.